|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12...35363738394041424344454647» |
- Clinical: The Efficacy of Robot Assisted Group Cognitive Training in Elderly Adults Without Cognitive Impairment (clinicaltrials.gov) - May 8, 2012
P=N/A, N=85, Completed, Sponsor: Samsung Medical Center
- || New P3 trial: Multicenter Vitamin E Trial in Aging Persons With Down Syndrome (clinicaltrials.gov) - May 7, 2012
P3, N=349, Completed, Sponsor: New York State Institute for Basic Research
- Trial completion, HEOR: Enhancing Quality of Life for Nursing Home Residents (clinicaltrials.gov) - May 7, 2012
P2, N=128, Completed, Sponsor: Penn State University
Active, not recruiting --> Completed
- Enrollment open: Use of Alternative Medicine in Patients With Dementia and Mild Cognitive Dysfunction (clinicaltrials.gov) - May 5, 2012
P=N/A, N=150, Recruiting, Sponsor: University Hospital of North Norway
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| rivastigmine transdermal / Generic mfg.
Enrollment change, Compliance: Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. (clinicaltrials.gov) - May 3, 2012
P4, N=380, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=300 --> 380
- |||| rivastigmine transdermal / Generic mfg.
Trial completion, Compliance: Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. (clinicaltrials.gov) - May 3, 2012
P4, N=380, Completed, Sponsor: Novartis Pharmaceuticals
N=300 --> 380 Recruiting --> Completed
- ||| Biomarker: A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery (clinicaltrials.gov) - May 3, 2012
P=N/A, N=600, Recruiting, Sponsor: Sanguine Biosciences
- Clinical: REGISTRY-JHD - an Observational Study of the European Huntington's Disease Network (EHDN) (clinicaltrials.gov) - May 1, 2012
P=N/A, N=50, Recruiting, Sponsor: European Huntington's Disease Network
- Clinical: REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) (clinicaltrials.gov) - May 1, 2012
P=N/A, N=10000, Recruiting, Sponsor: European Huntington's Disease Network
- ||||| PBT2 / Alterity Therap
New P2 trial: Reach2HD: Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease (clinicaltrials.gov) - May 1, 2012
P2, N=109, Completed, Sponsor: Prana Biotechnology Limited
- | armodafinil / Generic mfg.
Trial completion: "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" (clinicaltrials.gov) - May 1, 2012
P4, N=20, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed Enrolling by invitation --> Completed
- ||| Trial completion: Does Zumba Improve Cognition in Healthy APOE e4 Carriers and Noncarriers (clinicaltrials.gov) - May 1, 2012
P=N/A, N=65, Completed, Sponsor: Mayo Clinic
Enrolling by invitation --> Completed Enrolling by invitation --> Completed
- | donepezil / Generic mfg.
Trial completion: Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia (clinicaltrials.gov) - May 1, 2012
P4, N=36, Completed, Sponsor: Eisai Inc.
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- Trial completion: IBVM001: Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease (clinicaltrials.gov) - May 1, 2012
P2, N=26, Completed, Sponsor: Institute for Neurodegenerative Disorders
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: Meditation or Education for Alzheimer Caregivers (clinicaltrials.gov) - Apr 30, 2012
P2, N=108, Active, not recruiting, Sponsor: Oregon Health and Science University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | nelonicline (ABT-126) / AbbVie
Trial completion: A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Apr 30, 2012
P1, N=20, Completed, Sponsor: Abbott
Recruiting --> Active, not recruiting Recruiting --> Completed
- haloperidol / Generic mfg.
Enrollment open: Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol (clinicaltrials.gov) - Apr 26, 2012
P4, N=68, Recruiting, Sponsor: Northeastern University
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change, MRI: AMIMAGE: Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects (clinicaltrials.gov) - Apr 26, 2012
P=N/A, N=318, Completed, Sponsor: University Hospital, Bordeaux
Not yet recruiting --> Recruiting N=400 --> 318
- Enrollment change: DIF2: A Support Program for Carers of Persons With Dementia (clinicaltrials.gov) - Apr 24, 2012
P=N/A, N=230, Active, not recruiting, Sponsor: Norwegian Centre for Ageing and Health
N=400 --> 318 N=320 --> 230
- Enrollment closed: DIF2: A Support Program for Carers of Persons With Dementia (clinicaltrials.gov) - Apr 24, 2012
P=N/A, N=230, Active, not recruiting, Sponsor: Norwegian Centre for Ageing and Health
N=320 --> 230 Recruiting --> Active, not recruiting
- ||||| rivastigmine transdermal / Generic mfg., rivastigmine / Generic mfg.
New P4 trial: Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia (clinicaltrials.gov) - Apr 23, 2012
P4, N=127, Recruiting, Sponsor: Novartis Pharmaceuticals
- Enrollment change: A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease (clinicaltrials.gov) - Apr 22, 2012
P2, N=135, Completed, Sponsor: University of Massachusetts, Worcester
Recruiting --> Active, not recruiting N=300 --> 135
- Enrollment change: CHoPA-I: Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia (clinicaltrials.gov) - Apr 22, 2012
P3, N=40, Completed, Sponsor: University Hospital, Lille
N=300 --> 135 N=60 --> 40
- Trial completion: A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease (clinicaltrials.gov) - Apr 22, 2012
P2, N=135, Completed, Sponsor: University of Massachusetts, Worcester
N=60 --> 40 Recruiting --> Completed
- Trial completion: CHoPA-I: Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia (clinicaltrials.gov) - Apr 22, 2012
P3, N=40, Completed, Sponsor: University Hospital, Lille
Recruiting --> Completed Recruiting --> Completed
- |||||||||| New P3 trial: ARTEMIDA: Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI) (clinicaltrials.gov) - Apr 19, 2012
P3, N=500, Active, not recruiting, Sponsor: Takeda
- | GSK356278 / GSK
Trial completion: A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 (clinicaltrials.gov) - Apr 18, 2012
P1, N=36, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Completed
- Neurostem (human umbilical cord blood derived allogeneic mesenchymal stem cells) / Medipost
Trial completion: The Safety and The Efficacy Evaluation of NEUROSTEM (clinicaltrials.gov) - Apr 18, 2012
P1, N=9, Completed, Sponsor: Medipost Co Ltd.
Recruiting --> Completed Recruiting --> Completed
- || New P3 trial: OculoMacl: Oculomotor Testing in the Differential Diagnosis of Dementia (clinicaltrials.gov) - Apr 11, 2012
P3, N=100, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- ||||| galantamine hydrobromide / Generic mfg.
Enrollment change: An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine (clinicaltrials.gov) - Apr 10, 2012
P3, N=1083, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed N=2058 --> 1083
- | GSK356278 / GSK
New P1 trial: A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 (clinicaltrials.gov) - Apr 8, 2012
P1, N=36, Completed, Sponsor: GlaxoSmithKline
- Enrollment change: MAX: The Mental Activity and eXercise Trial for Seniors (clinicaltrials.gov) - Apr 5, 2012
P=N/A, N=126, Completed, Sponsor: University of California, San Francisco
N=2058 --> 1083 N=200 --> 126
- Trial completion: MAX: The Mental Activity and eXercise Trial for Seniors (clinicaltrials.gov) - Apr 5, 2012
P=N/A, N=126, Completed, Sponsor: University of California, San Francisco
N=200 --> 126 Active, not recruiting --> Completed
- ||||| Enrollment change: Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain (clinicaltrials.gov) - Apr 5, 2012
P3, N=226, Completed, Sponsor: Avid Radiopharmaceuticals
Active, not recruiting --> Completed N=152 --> 226
- lorazepam / Generic mfg., dexmedetomidine / Generic mfg.
Clinical: Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) (clinicaltrials.gov) - Apr 4, 2012
P4, N=150, Recruiting, Sponsor: Denver Health and Hospital Authority
N=152 --> 226 Initiation date: Aug 2011 --> Mar 2012
- lorazepam / Generic mfg., dexmedetomidine / Generic mfg.
Clinical: Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) (clinicaltrials.gov) - Apr 4, 2012
P4, N=150, Recruiting, Sponsor: Denver Health and Hospital Authority
Initiation date: Aug 2011 --> Mar 2012 Not yet recruiting --> Recruiting
- New P1 trial: Impact of Grape Consumption on Brain Metabolism and Cognitive Function (clinicaltrials.gov) - Apr 4, 2012
P1, N=12, Recruiting, Sponsor: University of California, Los Angeles
- ||| AZD3839 / AstraZeneca
Biomarker, Trial completion: Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers (clinicaltrials.gov) - Apr 4, 2012
P1, N=72, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial withdrawal, MRI: Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=0, Withdrawn, Sponsor: Kettering Health Network
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change, MRI: Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=0, Withdrawn, Sponsor: Kettering Health Network
Not yet recruiting --> Withdrawn N=30 --> 0
- Biomarker, Enrollment closed: Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=16, Active, not recruiting, Sponsor: Salena Killion
N=30 --> 0 Recruiting --> Active, not recruiting
- ||| elenbecestat (E2609) / Eisai, Biogen
Trial completion: Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort (clinicaltrials.gov) - Apr 3, 2012
P1, N=73, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial initiation date, MRI: Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease (clinicaltrials.gov) - Apr 2, 2012
P=N/A, N=0, Withdrawn, Sponsor: University Hospital, Strasbourg, France
Recruiting --> Completed Initiation date: Oct 2011 --> Apr 2012
- |||| Trial completion: Prospective Research in Memory Clinics (PRIME) (clinicaltrials.gov) - Apr 2, 2012
P4, N=970, Completed, Sponsor: Janssen-Cilag Pty Ltd
Initiation date: Oct 2011 --> Apr 2012 Active, not recruiting --> Completed
- | Trial completion: Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia (clinicaltrials.gov) - Apr 1, 2012
P=N/A, N=20, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial completion: Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Mar 29, 2012
P2, N=409, Completed, Sponsor: FORUM Pharmaceuticals Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Enrollment change: Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease (clinicaltrials.gov) - Mar 27, 2012
P1, N=80, Completed, Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Active, not recruiting --> Completed N=24 --> 80
- ||||| Trintellix (vortioxetine) / Lundbeck, Takeda
New P2 trial: Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder (clinicaltrials.gov) - Mar 26, 2012
P2, N=602, Completed, Sponsor: Takeda
- Clinical: A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers (clinicaltrials.gov) - Mar 26, 2012
P0, N=32, Completed, Sponsor: Avid Radiopharmaceuticals
- | New P1 trial: A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers (clinicaltrials.gov) - Mar 26, 2012
P1, N=25, Completed, Sponsor: Avid Radiopharmaceuticals